An international group of researchers examined quality of life factors for ovarian cancer patients enrolled in a large European clincial trial (EORTC 55971). They compared the quality of life patients who had primary debulking surgery versus those who had neo-adjuvant chemotherapy, followed by surgery.
The results, which are published in the journal Gynecologic Oncology, showed that survival and quality of life after neo-adjuvant chemo therapy followed by surgery was similar to survival and quality of life after primary debulking surgery followed by chemotherapy. However, institutions with good quality of life compliance had higher optimal debulking rates, and better survival outcomes.
Click here to read the abstract.
